2-甲基-2-[4-[2-甲基-8-[(吡啶-3-基)乙炔基]咪唑并[4,5-c]喹啉-1-基]苯基]丙腈 | 853910-02-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2-甲基-2-[4-[2-甲基-8-[(吡啶-3-基)乙炔基]咪唑并[4,5-c]喹啉-1-基]苯基]丙腈
• 中文别名: 2-甲基-2-[4-[2-甲基-8-[(吡啶-3-基)乙炔基]咪唑并[4,5-C]喹啉-1-基]苯基]丙腈；NVP-BAG956;2-甲基-2-[4-[2-甲基-8-[(吡啶-3-基)乙炔基]咪唑并[4,5-c]喹啉-1-基]苯基]丙腈
• 英文名称: NVP-BAG956
• 英文别名: 2-methyl-2-(4-(2-methyl-8-(pyridin-3-ylethynyl)-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile；BAG 956；2-methyl-2-[4-(2-methyl-8-pyridin-3-ylethynyl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile；2-methyl-2-[4-[2-methyl-8-(2-pyridin-3-ylethynyl)imidazo[4,5-c]quinolin-1-yl]phenyl]propanenitrile
• CAS: 853910-02-8
• 化学式: C₂₈H₂₁N₅
• 分子量: 427.508
• InChiKey: GVPAGJWVBUZHNQ-UHFFFAOYSA-N

物化性质

• 熔点：
  >224oC (dec.)
• 沸点：
  694.8±65.0 °C(Predicted)
• 密度：
  1.17
• 溶解度：
  DMSO（微溶，加热）、甲醇（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-乙炔基吡啶 、 NVP-BAG956中间体 在 二(氰基苯)二氯化钯 copper(l) iodide 、 三叔丁基膦 作用下， 以 1,4-二氧六环 、 N-甲基吡咯烷酮 为溶剂， 生成 2-甲基-2-[4-[2-甲基-8-[(吡啶-3-基)乙炔基]咪唑并[4,5-c]喹啉-1-基]苯基]丙腈
  参考文献：
  名称：

  Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway

  摘要：

  Imidazo[4,5-c]quinoline derivatives have been discovered and developed as potent and effective modulators of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) pathway to lead to clinical development candidates. The SAR data of representative examples of this compound class and their biological profiling in cellular and in vivo settings are presented and discussed. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.018

文献信息

• [EN] 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES<br/>[FR] DERIVES D'1H-IMIDAZO[4,5-C]QUINOLINE DANS LE TRAITEMENT DE MALADIES DEPENDANT DE LA PROTEINE KINASE
  申请人：NOVARTIS AG

  公开号：WO2005054238A1

  公开（公告）日：2005-06-16

  The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.

  该发明涉及咪唑喹啉及其盐在治疗蛋白激酶疾病以及用于制备治疗该疾病的药物制剂中的应用，咪唑喹啉用于治疗蛋白激酶依赖性疾病，一种治疗上述疾病的方法，包括向温血动物，特别是人类，给予咪唑喹啉，包含咪唑喹啉的药物制剂，特别用于治疗蛋白激酶依赖性疾病，新型咪唑喹啉，以及制备新型咪唑喹啉的方法。
• 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases
  申请人：Capraro Hans-Georg

  公开号：US20070213355A1

  公开（公告）日：2007-09-13

  The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.

  本发明涉及在蛋白激酶依赖性疾病治疗中使用咪唑喹啉及其盐，并用于制造用于治疗该类疾病的药物制剂，咪唑喹啉用于治疗蛋白激酶依赖性疾病，一种治疗该类疾病的方法，包括向温血动物尤其是人类施用咪唑喹啉，包括咪唑喹啉的药物制剂，特别是用于治疗蛋白激酶依赖性疾病的药物制剂，新型咪唑喹啉以及制备新型咪唑喹啉的方法。
• Producing mesodermal cell types and methods of using the same
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US10787640B2

  公开（公告）日：2020-09-29

  Methods are provided for the generation of mesodermal cell types and derivatives thereof. Also provided are methods for generating purified populations of mesodermal cell types and derivatives thereof. The instant disclosure also provides methods of screening for cellular responses of the generated mesodermal cell types and derivatives thereof. Also provide are methods for screening for organismal phenotypes induced by introduction of the generated mesodermal cell types and derivatives thereof. Treatment methods making use of the generated mesodermal cell types and derivatives thereof are also provided. The instant disclosure also provides systems, compositions, and kits for practicing the methods of the disclosure.

  提供了生成中胚层细胞类型及其衍生物的方法。还提供了生成纯化的中胚层细胞类型及其衍生物的方法。本发明还提供了筛选所产生的中胚层细胞类型及其衍生物的细胞反应的方法。本发明还提供了通过引入所产生的中胚层细胞类型及其衍生物来筛选生物表型的方法。还提供了利用生成的中胚层细胞类型及其衍生物的治疗方法。本发明还提供了用于实施本发明方法的系统、组合物和试剂盒。
• 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES
  申请人：Novartis AG

  公开号：EP1689747A1

  公开（公告）日：2006-08-16
• TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
  申请人：Vascular Biogenics Ltd.

  公开号：EP2791101B1

  公开（公告）日：2019-09-18